NCT05219669View on ClinicalTrials.gov

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

November 19, 2021

Study Completion Date

November 22, 2021

Conditions
Opioid Overdose
Interventions
DRUG

Nalmefene Hydrochloride

30 mg/mL solution

Trial Locations (1)

78217

WorldWide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Opiant Pharmaceuticals Inc

INDUSTRY